Authors

Latest:

Drs El-Khoueiry and Hughes-Halbert on the Importance of a Multidisciplinary Approach in Cancer Care

Anthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Edward S. Kim, MD, MBA

Latest:

Key Takeaways in HER2-Mutated NSCLC

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

Elizabeth Lihua Budde, MD, PhD

Latest:

Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.

Elizabeth Diaz, PA-C

Latest:

Remaining Unmet Needs for Patients With HR+/HER2- mBC

Experts highlight some remaining unmet needs in the treatment and management of patients with HR+/HER2- metastatic breast cancer.

Ken Kato, MD, PhD, National Cancer Center Hospital East

Latest:

Global Updates in Advanced Gastric Cancer from ESMO 2020

Afsaneh Barzi, MD, PhD, City of Hope

Latest:

Dr. Barzi on the Need for More Sensitive MRD Testing in CRC

Afsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.

Allegheny Health Network

Latest:

Expert Teams, Exceptional Outcomes: AHN Cancer Institute’s Disease Site Centers Drive Innovation

AHN Cancer Institute’s Centers of Excellence unite teams of experts to provide patients with high-quality, collaborative care in a supportive environment.

Salvatore Nardello, DO

Latest:

Fellows on Film: How To Market Yourself for a Fellowship

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.

Brian Till, MD

Latest:

Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCL

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.

Megan M. Dupuis, MD

Latest:

Choosing Your Path

Megan M. Dupuis, MD, shares the complex journey she traveled during medical training and how it brought her to the academic setting.

Jens Hillengass, MD, PhD

Latest:

Dr Hillengass on the Rationale For Investigating the Effect of Exercise on Functional Performance in Multiple Myeloma

Jens Hillengass, MD, PhD, discusses the rationale for investigating exercise and its effect on functional performance in multiple myeloma, and highlights the methods utilized in this study.

Rory Shallis, MD

Latest:

Dr Shallis on Data for Pembrolizumab Plus Venetoclax/Azacitidine in AML

Rory Shallis, MD, discusses the addition of pembrolizumab to azacitidine citidine and venetoclax in patients with acute myeloid leukemia.

Jeremy Kratz, MD

Latest:

Targeting Transcription as a New Frontier in Advanced Pancreatic Cancer

A new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.

Elias Bou Farhat, MD

Latest:

Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer

Elias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.

Muhamed Baljevic, MD

Latest:

Dr Baljevic on Selinexor Plus Pomalidomide/Dexamethasone in R/R Myeloma

Muhamed Baljevic, MD, discusses the efficacy and safety of selinexor in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Daniel M. Halperin, MD,

Latest:

Dr Halperin on the FDA Approval of Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs

Daniel M. Halperin, MD, discusses the FDA approval of lutetium Lu 177 dotatate for pediatric patients with SSTR-positive GEP-NETs.

Aron Simkins, MD

Latest:

Oncology Fellows Derive the Greatest Benefit From Advanced Research Training

Aimed at growing the translational workforce, most hubs offer different accelerated advanced degree opportunities to oncology trainees, such as master’s degrees in clinical and/or translational research, or graduate certificates.

Nitin Ohri, MD

Latest:

A Gut Check on the Digital Divide: How Wearable Devices Are Changing Cancer Care

The idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.

Julie Lang, MD

Latest:

Dr. Lang on the Potential Applications for the Parsortix® PC1 System in Breast Cancer

Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.

Misako Nagasaka, MD, PhD

Associate Clinical Professor, Division of Hematology/Oncology, Medicine

Latest:

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

Dr Nagasaka discusses the use of T-DXd in patients with unresectable or metastatic HER2-positive NSCLC.